Merck looks at M&A deals as COVID hits sales in Q1

Ken Frazier's final appearance on Merck & Co's financial results call as chief executive was a muted affair, as the company reported lower-than-expected revenues dragged down as the pan

COVID-19 drives Boehringer's R&D spend to record level in 20...

Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised its scientists to seek out new therapies for COVID-19. 

Vaccine sales recover at GSK in Q3, but lockdown fears weigh...

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end

COVID-19 bites into Pfizer’s Q3, but biopharma revenues rise

Pfizer is one of the front-runners in the race to approve a COVID-19 vaccine

GSK starts 2020 on a high, but warns of tougher times ahead

Pfizer will start COVID-19 vaccine trial in US next week